RO-3306 is widely used in biochemical and biomedical research as a selective inhibitor of cyclin-dependent kinase 1 (CDK1). It plays a critical role in cell cycle studies, particularly in blocking the G2 to M phase transition, allowing scientists to synchronize cells at specific cell cycle stages. This property makes it valuable for investigating cell division mechanisms, DNA damage responses, and mitotic entry controls. In cancer research, RO-3306 is employed to study the dependence of tumor cells on CDK1 activity, helping to assess the potential of CDK-targeted therapies. Due to its reversibility, cells can resume normal cycle progression after removal, enabling precise temporal control in experimental setups. It is also used in combination with other kinase inhibitors to explore synthetic lethality or pathway redundancies in cell proliferation and survival. Additionally, RO-3306 has been utilized in studies of neuronal differentiation and stem cell development, where controlled cell cycle arrest supports the examination of differentiation triggers. Its selectivity and effectiveness in cellular models make it a preferred tool compound in mechanistic studies of cell cycle regulation.